Literature DB >> 20542773

Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry.

Anna Norhammar1, Bo Lagerqvist, Nawsad Saleh.   

Abstract

AIMS: Patients with diabetes mellitus have poorer outcome following acute coronary syndromes and coronary revascularisation. Knowledge of long-term outcome after revascularisation in real-life situations is though limited was analysed. METHODS AND
RESULTS: Patients included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) in 2002-2007 with no previous revascularisation were followed for mortality after a first PCI until the end of 2007 (mean follow-up time 1,059 days). Differences in background and procedural characteristics were adjusted for in a multivariable Cox regression model. Of 57,708 patients, 18.8% had diabetes. Absolute mortality rate after four years follow-up was after STEMI, non-ST-elevation ACS and stable CAD respectively 23.2%, 17.8% and 12.7% for persons with diabetes and 14.4%, 8.4% and 5.7% for persons without diabetes. Adjusted relative risk for long-term mortality after first PCI was higher in patients with diabetes compared with those without; RR (95% CI); 1.66 (1.33-1.72), and after all three different PCI indications; RR (95% CI) for CAD; 2.01 (1.69-2.40), non-ST-elevation ACS 1.73 (1.58-1.90) and STEMI 1.44(1.30-1.59).
CONCLUSIONS: Long-term mortality is higher in diabetic patients compared with those without, after a first PCI and this mortality gap increases with follow-up time. Intensive secondary preventive measures are needed to improve this situation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542773     DOI: 10.4244/

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  8 in total

Review 1.  Medical management of chronic stable angina.

Authors:  Yong Wee; Kylie Burns; Nicholas Bett
Journal:  Aust Prescr       Date:  2015-08-03

2.  Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment.

Authors:  N Saleh; P Petursson; B Lagerqvist; H Skúladóttir; A Svensson; B Eliasson; S Gudbjörnsdottir; K Eeg-Olofsson; A Norhammar
Journal:  Diabetologia       Date:  2012-05-08       Impact factor: 10.122

Review 3.  Type 2 diabetes and cardiovascular disease in women.

Authors:  A Norhammar; K Schenck-Gustafsson
Journal:  Diabetologia       Date:  2012-09-04       Impact factor: 10.122

4.  Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention.

Authors:  Hidehiro Kaneko; Junji Yajima; Yuji Oikawa; Shingo Tanaka; Daisuke Fukamachi; Shinya Suzuki; Koichi Sagara; Takayuki Otsuka; Shunsuke Matsuno; Hiroto Kano; Tokuhisa Uejima; Akira Koike; Kazuyuki Nagashima; Hajime Kirigaya; Hitoshi Sawada; Tadanori Aizawa; Takeshi Yamashita
Journal:  Heart Vessels       Date:  2013-06-27       Impact factor: 2.037

5.  A review of cardiovascular outcomes in the treatment of people with type 2 diabetes.

Authors:  George Dailey; Edward Wang
Journal:  Diabetes Ther       Date:  2014-12-17       Impact factor: 2.945

6.  Predictive Value of Gensini Score in the Long-Term Outcomes of Patients With Coronary Artery Disease Who Underwent PCI.

Authors:  Kai-Yang Wang; Ying-Ying Zheng; Ting-Ting Wu; Yi-Tong Ma; Xiang Xie
Journal:  Front Cardiovasc Med       Date:  2022-01-24

7.  Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population.

Authors:  Xingli Wu; Dingyou Yang; Yusheng Zhao; Caiyi Lu; Yu Wang
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

8.  Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention.

Authors:  Mao-Jen Lin; Jung Lee; Chun-Yu Chen; Chia-Chen Huang; Han-Ping Wu
Journal:  BMC Cardiovasc Disord       Date:  2017-09-11       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.